Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication: A Pilot Study Examining the Role of Dopamine

Journal of Nervous and Mental Disease

Volumn 184, Issue 5, 1996, Pages 295-301

  Bodkin, J Alexander ^a   Cohen, Bruce M ^a   Salomon, Melinda S ^a,b   Cannon, Sophie E ^c   Zornberg, Gwen L ^a,d   Cole, Jonathan O ^a,e  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c William James College   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DEPRESSIVE DISORDER; DOPAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELEGILINE; SEVERITY OF ILLNESS INDEX;

EID: 0030027886     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005053-199605000-00005     Document Type: Article

References (64)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders 3rd Ed., Revised. Washington, DC: Author.
2. Andreasen NC (1982) Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39:784-780.
3. Andreasen NC, Olsen S (1982) Negative and positive schizophrenia: Definition and validation. Arch Gen Psychiatry 39: 789-794.
4. Angrist B, Peselow P, Rubinstein M, Corwin J, Rotrosen J (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 78:128-130.
5. Baldessarini R (1985) Chemotherapy in psychiatry: Principles and practice, 2nd Ed. Cambridge: Harvard University Press.
6. Belmaker R, Wald D (1977) Haloperidol in normals. Br J Psychiatry 137:222-223.
7. Bermanzohn PC, Siris SG (1992) Akinesia: A syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry 33:221-232.
8. Bodkin JA (1990) Emerging uses of high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 55(Suppl 5): 41-46.
9. Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91:104-108.
10. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:440-452.
11. Carpenter WT, Heinrichs DW, Wagman AM, Althea MI (1988) Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 5:578-583.
12. Carroll B (1991) Psychopathology and neurobiology of manic depressive disorders. In JE Barrett (Ed), Psychopathology and the brain (pp 265-285). New York: Raven Press.
13. Casey DT (1994) Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl 380:14-20.
14. Cloninger R (1987) Systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry 44:573-588.
15. Cole JO, Jones RT, Klerman GL (1961) Drug therapy. Prog Neurot Psychiatry 16:539-574.
16. Crow TS (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280:66-68.
17. Csernansky J, Riney S, Lombrozo L, Overall J, Hollister L (1988) Double-blind comparison of alprazolam, diazepam and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 45:655-671.
18. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486.
19. Depue R, Spoont M (1986) Conceptualizing a serotonin trait: A behavioral method of constraint. Ann N Y Acad Sci 487:47-62.
20. Dimascio A (1963) The psychopharmacology of phenothiazines. J Nerv Ment Dis 136:168-186.
21. Goldberg S (1989) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Br J Psychiatry 155(Suppl 7): 128-132.
22. Gray J (1991) Neural systems, emotion and personality. In J Madden (Ed), Neurobiology of learing, emotion and affect (pp 273-306). New York: Raven Press.
23. Guy W (1976) ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. Dept. Health, Education, and Welfare.
24. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 10:799-812.
25. Harrow M, Yonan CA, Sands JR, Marengo J (1994) Depression in schizophrenia: Are neuroleptics, akinesia or anhedonia involved? Schizophr Bull 20:327-337.
26. Kamman GR, Freeman JG, Lucero R (1953) The effect of iproniazid on the behavior of long-term mental patients. J Nerv Ment Dis 118:3911-407.
27. Klerman G, Dimascio A, Havens LS (1960) Sedation and tranquilization. Arch Gen Psychiatry 3:4-13.
28. Lader M (1993) Neuroleptic induced deficit syndrome: Old problem, new challenge. J Psychopharmacol 7:392-393.
29. Lees A (1991) Selegiline hydrochloride and cognition. Acta Neurol Scand Suppl 136:91-94.
30. Levi-Minzi S, Bermanzohn P, Siris S (1991) Bromocriptine for negative schizophrenia. Compr Psychiatry 32:210-216.
31. Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 380:8-13.
32. MacKay AVP (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137:379-386.
33. Magliozzin J, Mangas S, Laubly J, Blunder D (1989) Effect of haloperidol on digit substitution test in normal adult males. Neuropharmacology 2:29-37.
34. Mann J, Aarons S, Wilner P, Keilp J, Sweeney J, Pearlstein T, Francis A, Kocsis J, Brown R (1989) A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45-50.
35. Mann J, Gershon S (1980) L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26:877-882.
36. McGlashan T, Carpenter W (1976) Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 33:231-239.
37. McGrath P, Stewart J, Harrison W (1989) A placebo-controlled trial of 1-deprenyl in atypical depression. Psychopharmacol Bull 25:63-68.
38. McNair D, Lorr M, Droppleman L (1978) Manual for profile of mood states. San Diego, CA: Educational and Industrial Testing Service.
39. Meltzer HY, Burnett S, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life in chronic schizophrenic patients. Hosp Community Psychiatry 41:892-897.
40. Mendis N, Pare CMB, Sandler MG, Stein M (1981) Is failure of I-deprenyl, a selective monoamine oxidase-B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73:87-90.
41. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812.
42. Perenyi A, Goswami U, Frecska E, Arato M, Bela A (1991) L-deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 42:188-191.
43. Prosser E, Csernansky J, Kaplan J, Thiemann S, Becker T, Hoilister L (1987) Depression, parkinsonian symptoms and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 175:100-105.
44. Quitkin FM, Liebowitz MR, Stewart JG, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-deprenyl in atypical depressives. Arch Gen Psychiatry 41:777-781.
45. Samson JA, Gurrera RJ, Nisenson L, Schildkraut JJ (1995) Platelet MAO activity and deficit syndrome schizophrenia. Psychiatry Res 56:25-31.
46. Samson JA, Young A, Tsuang M (1989) Negative symptoms in schizophrenia: Depressive or deficit syndrome. In: R Williams, TJ Dalby, (Eds), Depression in Schizophrenics (p. 53-66). New York: Plenum Press.
47. Schooler NR (1994) Deficit symptoms in schizophrenia: Negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl 380:21-26.
48. Seibyl J, Krystal J, Brenner L, Erdos J, Johnson R, Karper L, Charney D (in press) Mazindole augmentation of neuroleptic in negative symptom schizophrenia: Preliminary placebo-controlled double-blind and open-label extension studies. J Clin Psychopharmacol.
49. Simpson G, Angus J (1970) Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl 212(suppl):11-19.
50. Siris S (1995) Depression and schizophrenia. In S Hirsch, D Weinberg (Eds), Schizophrenia. London: Blackwell Publications.
51. Siris S, Adam F, Cohen M, Mendeli J, Aronson A, Casey E (1988) Post-psychotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 145:1532-1537.
52. Siris SG, van Kammen DP, Docherty JP (1978) The use of anti-depressant medications in schizophrenia: A review of the literature. Arch Gen Psychiatry 35:1368-1377.
53. Strauss JS, Carpenter WT, Bartko JJ (1974) Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1(Experimental issue No. 11):G1-69.
54. Strauss J, Rakfeldt J, Harding C, Lieberman P (1989) Psychological and social aspects of negative symptoms. Br J Psychiatry 155(Suppl 7):128-132.
55. Sunderland T, Cohen R, Molchan S, Lawlor P, Mellow A, Newhouse P, Tariot P, Mueller E, Murphy D (1994) High dose selegiline in treatment resistant older depressive patients. Arch Gen Psychiatry 51:607-615.
56. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86:432-437.
57. Tyrer P (1976) Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 128:354-360.
58. Van Kammen D, Boronow J (1988) Dextroamphetamine diminishes negative symptoms in schizophrenia. Int J Clin Psychopharmacol 3:111-121.
59. Van Praag H, Sanis G, Kahn R, Brown S, Korn M, Harkavey M, Friedman J, Wetlzler S (1990) Monoamines and abnormal behavior: A multi-aminergic perspective. Br J Psychiatry 157: 723-734.
60. Van Putten T, Marder SR (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48:13-19.
61. Waters CH (1994) Fluoxetine and selegiline - Lack of a significant interaction. Can J Neurol Sci 21:259-261.
62. Weinberger D (1987) The implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
63. Wing JK, Brown GW (1970) Institutionalism and schizophrenia. Cambridge: Cambridge University Press.
64. Yu PH, Bouton AA (1994) Clinical pharmacology of MAO-B inhibitors. In SH Kennedy (Ed), Clinical advances in monoamine oxidase inhibitor therapies (pp 61-82). Washington DC: APA Press.